Xencor, Inc.
ANTI-CD28 COMPOSITIONS

Abstract:

Provided herein are novel anti-CD28.times.anti-B7H3 (also referred to as ".alpha.CD28.times..alpha.B7H3") heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject .alpha.CD28.times..alpha.B7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.